Photo credit: usatoday.com

COVID-19 Prevention, Control, and Treatment | Moderna Vaccine Booster

Coronavirus Public Health care Delivery Education

The Centers for Disease Control and Prevention (CDC) backs roll out of Moderna and Johnson & Johnson COVID-19 vaccine boosters 

• Facebook
• Twitter
• Pinterest

The Centers for Disease Control and Prevention supports the launch of the Modern and Johnson & Johnson COVID-19 vaccine booster in line with the Food and Drug Administration approval issued Wednesday. The CDC also supports a mixed and suitable approach to booster vaccination.

The announcement is coming just hours after the CDC’s vaccine advisory committee voted unanimously in favour of booster doses following last week’s approval by FDA.

Moderna, Pfizer, and BioNTech boosters to be given to people aged 18 and above with certain medical conditions and at the risk of COVID-19, but Johnson & Johnson for people 18 and older at least two months after their initial immunization.

For Moderna, the panel said boosters should be given to people with the same conditions as Pfizer and BioNTech boosters. This would include people aged 65 years and over, people aged 18 years and over in long-term care facilities, and people aged 50 to 64 with relevant underlying medical conditions. Boosters can be given to people aged 18 to 49 years with certain medical conditions and to people aged 18 to 64 who are at risk of COVID19 due to their work or who live in certain institutional settings.

For Johnson & Johnson, the panel’s advice was simpler: A booster is recommended for people 18 and older at least two months after their initial immunization.

The CDC presentation and draft voting language state that the same vaccine used for initial immunization should be used as a booster dose, but that a mix-and-match approach is acceptable when a primary vaccine is not available or a  vaccine is preferred.

Read More from NPR

Watch video of Moderna and Johnson & Johnson COVID-19 Vaccine Booster Shots Approval by CDC

FDA recommends Moderna Booster shots and two-shot doses of messenger RNA Vaccine for older and vulnerable people

Moderna Inc’s COVID-19 Vaccine Booster shots have been unanimously recommended by a Food and Drug Administration (FDA) advisory panel to be people 65 and older and other vulnerable Americans who are at high risk of the disease.

Additional doses of the two-shot messenger RNA Vaccine should also be offered to people 65 years and above, along with adults 18 and older who are at high risk for medical or occupational reasons, THE Food and Drug Administration (FDA) Panel recommended in a 19-0 vote.

Booster from Pfizer Inc. BioNTech SE which has since been cleared by the FDA in the older and higher-risk population

The vote follows a similar recommendation from the panel on a booster from Pfizer Inc. BioNTech SE which has since been cleared by the FDA in older and higher-risk populations. Moderna had earlier presented data indicating that the vaccine loses its efficacy over time and that a booster shot is safer and can help restore the levels of protective antibodies.

A half-dose booster dose of Moderna vaccine at least six months after completion of the two-dose series.

The recommendation, which comes from the FDA’s Advisory Committee on Vaccines and Related Biological Products, says that older people and young adults with health or occupational problems that put them at increased risk of contracting COVID19 should receive a half-dose booster dose of Moderna vaccine at least six months after complete the two-dose series.

Other interesting Eduonwheels’ COVID-19 Vaccines, Prevention, Control, and Treatment-related posts in Public Health care Delivery Education you might like:

Fully homegrown COVID-19 Vaccine, Covaxin, approved for use in Children

Woman says even God cannot convince her to take COVID-19 Vaccine

A first home-used COVID-19 drug pill reduces death by 50%

Moderna booster 69 million Americans; Delta Variant infection slowing and FDA consider Johnson & Johnson vaccine booster shots

The FDA recommendation is non-binding but could help pave the way for a portion of the 69 million Americans who received the Moderna series to get a booster. 

The recommendations come as the country sees a general decline in COVID-19 cases, although the figure is still averaging 90,000 new infections and 1,800 deaths per day.

 After the delta variant led to an increase in cases in late summer, data from the Santa Barbara County Department of Public Health show that cases are decreasing locally.

The FDA is set to consider this recommendation from the panel later this week. The agency will also be discussing a booster shot of the Johnson & Johnson vaccine. 

Read More from Livingston County News

This blog content on ‘COVID-19 Prevention, Control, and Treatment: Moderna COVID-19 Vaccine Booster: FDA backs shots for older people and those at high risk of the disease ’ is categorized under Coronavirus Public Health care Education.

Our Public Health care Education System is about creating and delivering impacting, and empowering problem-solving information towards enhancing prevention and control of COVID-19 spread to our amiable readers for better health and sustainable livelihood – Eduonwheels.